Rizzo A.; Mollica V.; Santoni M.; Palmiotti G.; Massari F., Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis, «JOURNAL OF CLINICAL MEDICINE», 2022, 11, Article number: 1038, pp. 1 - 8 [articolo]Open Access
Santoni M.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Fragomeno B.; Battelli N.; Massari F., Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis, «EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH», 2022, 22, pp. 45 - 51 [articolo]
Massari F.; Mollica V., Personalizing immunotherapy for renal cell carcinoma: how far have we come?, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2022, 22, pp. 1221 - 1225 [articolo]
Ricci A.D.; Rizzo A.; Mollica V.; Schiavina R.; Fiorentino M.; Brunocilla E.; Ardizzoni A.; Massari F., Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data, «ANTI-CANCER DRUGS», 2022, 33, pp. e61 - e68 [articolo]
Iacovelli R.; Ciccarese C.; Maruzzo M.; Atzori F.; Galli L.; Scagliarini S.; Massari F.; Verzoni E.; Cannella A.; Maratta M.G.; Caserta C.; Bimbatti D.; Deppieri F.M.; Dessi M.; Paolieri F.; Riccardi F.; Bracarda S.; De Giorgi U.; Basso U.; Tortora G.; Procopio G., Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib, «CLINICAL GENITOURINARY CANCER», 2022, 20, pp. 498 - 498.e9 [articolo]
Mollica V.; Massari F.; Andrini E.; Rosellini M.; Marchetti A.; Nuvola G.; Tassinari E.; Lamberti G.; Campana D., Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis, «CURRENT ONCOLOGY», 2022, 29, pp. 5846 - 5854 [articolo]Open Access
Santoni M.; Molina-Cerrillo J.; Massari F.; Montironi R.; Grande E., Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study, «EUROPEAN UROLOGY», 2022, 81, pp. 623 - 624 [articolo]
Righini M.; Mollica V.; Rizzo A.; La Manna G.; Massari F., Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis, «JOURNAL OF CLINICAL MEDICINE», 2022, 11, Article number: 4373, pp. 1 - 17 [articolo]Open Access
Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Massari F., Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials, «FUTURE ONCOLOGY», 2022, 18, pp. 625 - 634 [articolo]
Orsatti, Agnese; Sirolli, Maria; Ambrosi, Francesca; Franceschini, Tania; Giunchi, Francesca; Franchini, Eugenia; Grillini, Marco; Massari, Francesco; Mollica, Veronica; Bianchi, Federico Mineo; Colecchia, Maurizio; Fiorentino, Michelangelo; Ricci, Costantino, SOX2 and PRAME in the "reprogramming" of seminoma cells, «PATHOLOGY, RESEARCH AND PRACTICE», 2022, 238, Article number: 154044, pp. 237 - 237 [articolo]
Santoni M.; Massari F.; Matrana M.R.; Basso U.; De Giorgi U.; Aurilio G.; Buti S.; Incorvaia L.; Rizzo M.; Martignetti A.; Maslov D.; Tawagi K.; Philon E.; Blake Z.; Porta C.; Battelli N., Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma, «EUROPEAN JOURNAL OF CANCER», 2022, 172, pp. 191 - 198 [articolo]
Santoni M.; Monteiro F.S.M.; Massari F.; Abahssain H.; Aurilio G.; Molina-Cerrillo J.; Myint Z.W.; Zabalza I.O.; Battelli N.; Grande E., Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2022, 176, Article number: 103731, pp. 103731 - 103738 [articolo]
Raschi E.; Fusaroli M.; Massari F.; Mollica V.; Repaci A.; Ardizzoni A.; Poluzzi E.; Pagotto U.; Di Dalmazi G., The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System, «THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM», 2022, 107, pp. 3107 - 3114 [articolo]Open Access
Nuvola G.; Rizzo A.; Mollica V.; Massari F., The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem?, «IMMUNOTHERAPY», 2022, 14, pp. 171 - 174 [articolo]
Rizzo A.; Santoni M.; Mollica V.; Ricci A.D.; Calabro C.; Cusmai A.; Gadaleta-Caldarola G.; Palmiotti G.; Massari F., The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis, «JOURNAL OF PERSONALIZED MEDICINE», 2022, 12, Article number: 842, pp. 1 - 8 [articolo]Open Access
